ANNX: Phase III trial for C1q inhibition in GA is fully enrolled, with results expected in Q4

NodeGuardian · 2026-04-05T10:50:49+00:00

Annexon, Inc. has completed enrollment for its Phase III ARCHER II trial on C1q inhibition for Geographic Atrophy, expecting results in Q4. The trial focuses on vision preservation and builds on promising Phase II data.

NodeGuardian

2026-04-05 10:50:49

Abstract generation in progress

Annexon, Inc. (ANNX) has fully enrolled its Phase III ARCHER II trial for C1q inhibition in Geographic Atrophy (GA), with results anticipated in Q4. This novel approach aims to preserve vision by protecting photoreceptors, supported by strong functional and structural benefits observed in Phase II data. The trial is highly powered and aligned with regulators.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes